Pathology CPT Codes in 2026: Billing & Modifier Guide

Pathology CPT codes define how laboratories, pathology groups, and healthcare organizations document diagnostic complexity, establish medical necessity, and secure reimbursement for pathology services across the U.S. healthcare system. 

In 2026, pathology billing has become increasingly complex as payers intensify scrutiny around molecular diagnostics, modifier usage, documentation specificity, and professional versus technical component billing.

From surgical pathology and frozen sections to flow cytometry and next-generation sequencing (NGS), accurate CPT coding directly affects reimbursement accuracy, denial prevention, and compliance performance. Even minor coding or documentation gaps can lead to delayed payments, payer audits, incorrect reimbursement, or claim rejections.

According to current CMS reimbursement trends and payer policy updates, pathology claims tied to immunohistochemistry (IHC), molecular pathology, oncology panels, and advanced diagnostic testing continue to face higher review rates in 2026 due to rising utilization and reimbursement complexity.

Successful pathology billing now requires more than correct code selection. Laboratories and pathology billing teams must align documentation, specimen classification, modifier usage, unit reporting, and payer-specific rules throughout the revenue cycle.

Surgical Pathology CPT Codes 88300 – 88309

Surgical pathology remains one of the highest-volume and highest-impact areas in pathology billing. These CPT codes classify specimens based on examination complexity, helping payers determine reimbursement levels.

One of the most common pathology billing mistakes occurs when specimen complexity documentation does not support the selected pathology level, especially for CPT code 88305.

Common Surgical Pathology CPT Codes

88300 → Gross Examination Only

CPT code 88300 is reported when a pathologist performs gross examination and documentation of a specimen without microscopic analysis. It commonly applies to foreign bodies, orthopedic hardware, or removed medical devices requiring identification and descriptive review but not detailed tissue pathology interpretation. 

88302 – 88309

The 88302–88309 code range covers surgical pathology services involving both gross and microscopic examination with increasing levels of specimen complexity.

88302 → Low-Complexity Surgical Pathology Examination

Used for low-complexity surgical pathology specimens requiring both gross and microscopic examination. Typical cases include minor tissue samples with limited diagnostic complexity. Proper specimen identification and pathology documentation are important because reimbursement depends heavily on accurate pathology level assignment and supporting clinical information. 

88304 → Intermediate-Complexity Surgical Pathology Examination

This pathology code supports intermediate-complexity specimen examinations involving routine gross and microscopic evaluation. Frequently reported for appendices, gallbladders, or benign lesions, the service requires documentation describing the specimen source, pathology findings, and diagnostic relevance supporting the selected pathology complexity level.  

88305 →Moderate-Complexity Surgical Pathology Examination

One of the most frequently billed pathology services, 88305 applies to moderate-complexity tissue examinations such as GI biopsies, skin biopsies, cervical biopsies, and breast tissue specimens. Because of its high utilization, payers closely monitor documentation specificity, specimen classification, and medical necessity support. 

88307 →High-Complexity Surgical Pathology Examination

Reserved for higher-complexity pathology examinations involving major resections or diagnostically complex tissue specimens. These cases often require extensive physician interpretation, additional microscopic review, and detailed reporting to support accurate diagnosis and justify the increased reimbursement associated with advanced pathology services. 

88309 →Highest-Complexity Surgical Pathology Examination

Assigned to highly complex pathology cases involving extensive diagnostic evaluation, commonly associated with major oncologic resections or advanced surgical specimens. Strong documentation should reflect significant physician work, detailed microscopic interpretation, and the complexity of the diagnostic decision-making process supporting this pathology classification. 

Revenue Impact

Surgical pathology coding directly affects pathology reimbursement because higher-complexity specimens typically involve greater physician work, interpretation time, and diagnostic resources. 

Practices that standardize specimen classification workflows often reduce undercoding and payer denials.

Intraoperative Consultation and Frozen Section CPT Codes

Intraoperative pathology services require precise documentation because reimbursement depends heavily on block counts, consultation type, and specimen handling during surgery.

Frozen section coding errors commonly occur when pathology teams fail to document the exact number of blocks, cytologic preparations, or consultation methods used during the operative workflow.

Key Frozen Section CPT Codes

88329 → Intraoperative Gross Examination

Used when a pathologist performs intraoperative gross examination during surgery without frozen section analysis. Findings are communicated directly to the surgical team to assist immediate operative decisions. Documentation should include specimen source, consultation details, and the information relayed during the intraoperative encounter.

88331 → Frozen Section Analysis, First Tissue Block

CPT code 88331 applies to the first frozen section tissue block examined during an intraoperative consultation. The service includes rapid tissue preparation, microscopic interpretation, and immediate communication of findings to the surgeon. Accurate documentation of specimen source and frozen block evaluation is essential for compliant billing.

88332 → Frozen Section Analysis, Each Additional Block

Reported as an add-on service for every additional frozen section tissue block evaluated during the same operative consultation. Proper billing depends on accurate block count tracking and documentation showing that each additional frozen section examination was separately performed and medically necessary during surgery.

88333 → Intraoperative Cytologic Evaluation, Initial Site

This code covers the first intraoperative cytologic evaluation, including touch preparations or smear assessments performed during surgery. These evaluations help determine tissue adequacy or malignancy presence in real time. Documentation should identify the specimen site, preparation method, and interpretation findings communicated intraoperatively.

88334 → Additional Intraoperative Cytologic Evaluation

CPT code 88334 is used for each additional intraoperative cytologic preparation evaluated beyond the initial site during surgery. Billing requires clear documentation supporting separate preparation sites, additional cytologic interpretation, and the clinical necessity for multiple evaluations performed during the operative procedure.

Workflow Impact

Accurate frozen section billing depends on:

• Surgeon request documentation
• Specimen source identification
• Frozen block counts
• Cytologic preparation tracking
• Add-on code validation

Coding Tip

Pathology teams should review NCCI edits regularly to prevent unbundling issues involving frozen section add-on services.

Revenue Impact

Frozen section services often involve high-value surgical cases. Accurate documentation and block tracking improve reimbursement precision while reducing audit exposure tied to intraoperative pathology billing.

Special Stains, IHC, IF, ISH, and Electron Microscopy Codes

Advanced pathology studies continue to expand in 2026 as oncology testing, precision medicine, and targeted diagnostics become more common.

Because these services often involve higher reimbursement levels, payers increasingly review unit reporting, medical necessity documentation, and antibody tracking.

Special Stains CPT Codes 88312–88319

The CPT code range 88312–88319 covers special stains and histochemical studies performed to identify microorganisms, tissue structures, cellular components, and disease processes not clearly visible with routine staining methods. 

These pathology services are commonly used for fungal identification, acid-fast bacteria detection, connective tissue evaluation, mucin studies, and histochemical analysis supporting more precise diagnostic interpretation and reimbursement accuracy. 

Revenue Impact

Special stains improve diagnostic specificity while supporting appropriate reimbursement for medically necessary supplemental pathology testing.

Immunohistochemistry (IHC) CPT Codes

88342 → Initial Immunohistochemistry (IHC) Antibody Stain

CPT code 88342 covers the first single-antibody immunohistochemistry stain performed on a specimen to evaluate tumor markers, tissue origin, or disease processes. Supporting documentation should identify the antibody used, specimen evaluated, diagnostic purpose, and interpretation findings establishing medical necessity for the study.

88341 → Additional Single Antibody IHC Stain

Used for each additional single-antibody immunohistochemistry stain performed on the same specimen after the initial stain. Because multiple antibody studies often trigger payer scrutiny, pathology teams should maintain detailed antibody tracking records and documentation supporting each additional stain reported.

88344 → Multiplex Immunohistochemistry Staining

CPT code 88344 applies to multiplex immunohistochemistry studies involving simultaneous evaluation of multiple antibodies on a single specimen slide. Frequently utilized in oncology and precision medicine diagnostics, these services require documentation supporting the multiplex methodology, antibody combinations used, and clinical significance of the pathology findings.

Why IHC Billing Faces Higher Audit Risk

In 2026, immunohistochemistry billing continues to receive elevated payer scrutiny because of increasing oncology testing utilization and higher reimbursement values.

Practices that standardize antibody tracking and unit reporting workflows are better positioned to defend claims during audits.

Immunofluorescence CPT Codes

88346 → Initial Immunofluorescence Antibody Stain

Assigned to the first immunofluorescence antibody stain performed during pathology evaluation. Commonly used in dermatopathology, renal pathology, and autoimmune disease testing, the service requires documentation identifying the antibody utilized, tissue examined, and interpretation findings supporting medical necessity for immunofluorescence analysis.

88350 → Additional Immunofluorescence Antibody Stain

Reported for each additional immunofluorescence antibody stain evaluated on the same specimen beyond the initial stain. Accurate unit reporting and antibody tracking are important because payer audits frequently review immunofluorescence claims for duplicate billing or unsupported additional testing utilization.

In-Situ Hybridization (ISH) CPT Codes 88365–88377

The CPT code range 88365–88377 covers in-situ hybridization (ISH) studies involving DNA and RNA probe testing used in oncology, genetic analysis, and infectious disease diagnostics. 

Pathology documentation should clearly identify the probe type, molecular target evaluated, testing methodology, clinical rationale, and interpretation of results supporting medical necessity and accurate molecular pathology reimbursement. 

88348 → Electron Microscopy Examination

Electron microscopy studies performed for selected renal, neuromuscular, or tumor pathology evaluations are billed using 88348. Documentation should explain why electron microscopy was necessary, how findings contributed to diagnosis, and the relationship between microscopic findings and the final pathology interpretation.

Coding Tip

Avoid outdated or deleted electron microscopy CPT codes within pathology templates or billing workflows.

Cytopathology and Pap Smear CPT Codes

Cytopathology billing remains one of the most misunderstood areas in pathology coding because interpretation services differ from specimen collection services.

Many billing errors occur when pathology teams incorrectly report cytology interpretation codes instead of clinic-based collection codes.

Common Cytopathology CPT Codes

88142 → Conventional Pap Smear Cytopathology

CPT code 88142 is used for cervical or vaginal cytopathology performed using conventional smear preparation methods with manual screening and interpretation. Proper reporting requires documentation of specimen adequacy, preparation methodology, interpretation results, and final cytologic diagnosis supporting gynecologic pathology services.

88175 → ThinPrep or Automated Pap Cytology

Assigned to automated or liquid-based cervical cytology testing involving thin-prep technology with manual rescreening and interpretation. These methods improve specimen preservation and diagnostic quality. Documentation should identify the preparation technique, adequacy assessment, interpretation findings, and follow-up recommendations provided.

Non-GYN Cytology and FNA Cytopathology

Non-gynecologic cytology billing requires clear documentation of specimen source, preparation method, and pathology interpretation.

Fine Needle Aspiration (FNA) Cytopathology Codes

88172 → Rapid Onsite Evaluation (ROSE) for FNA

Used when immediate adequacy assessment is performed during a fine needle aspiration procedure to determine whether collected material is diagnostically sufficient. Supporting documentation should include specimen source, adequacy findings, onsite evaluation details, and communication with the procedural or surgical team.

88173 → Final Interpretation of FNA Cytology

CPT code 88173 covers the final cytopathology interpretation and reporting of fine needle aspiration specimens following complete diagnostic review. 

Pathology documentation should identify specimen source, preparation methods, cytologic findings, diagnostic conclusions, and correlation with relevant clinical information supporting reimbursement requirements.

Revenue Impact

Proper FNA cytopathology billing improves reimbursement capture for onsite adequacy evaluations and final interpretation services.

Flow Cytometry CPT Codes

Flow cytometry plays a critical role in leukemia, lymphoma, and hematologic malignancy evaluation. Because these claims often involve multiple technical markers and separate professional interpretation services, incorrect marker counts frequently trigger reimbursement reductions or payer edits.

Common Flow Cytometry CPT Codes

88184 → First Flow Cytometry Marker Analysis

Reported for the first technical flow cytometry marker analyzed during immunologic or hematologic testing. Accurate billing depends on detailed marker tracking because reimbursement is closely tied to correct marker counts, technical component reporting, and compliance with payer-specific laboratory testing guidelines.

88185 → Each Additional Flow Cytometry Marker

CPT code 88185 applies to every additional technical flow cytometry marker analyzed beyond the initial marker during testing. Pathology teams should validate marker counts carefully because duplicate or unsupported additional marker reporting commonly results in reimbursement reductions or payer claim denials.

88187 → Flow Cytometry Interpretation, 2–8 Markers

Used for professional interpretation of flow cytometry testing involving two to eight markers. The pathologist evaluates immunophenotypic findings to support diagnosis of leukemia, lymphoma, or hematologic disorders. Documentation should correlate marker analysis with the final pathology interpretation and clinical presentation.

88188 → Flow Cytometry Interpretation, 9–15 Markers

This code supports professional interpretation of more complex flow cytometry studies involving nine to fifteen markers. These evaluations typically involve expanded hematologic analysis requiring detailed interpretation documentation to support reimbursement accuracy and defend claims during payer audits or medical review.

88189 → Flow Cytometry Interpretation, 16+ Markers

CPT code 88189 is reported for high-complexity flow cytometry interpretation involving sixteen or more markers, commonly associated with advanced leukemia or lymphoma workups. Documentation should reflect extensive interpretive analysis, diagnostic complexity, and clinical correlation supporting the medical necessity of the evaluation.

Coverage Considerations

Medicare and commercial payer policies may restrict billing combinations involving:

• 88184 – 88185
• Quantitative immunology codes
• Duplicate technical marker reporting

Revenue Impact

Flow cytometry reimbursement depends heavily on accurate marker tracking and interpretation documentation. Standardized workflows reduce underbilling risk and improve claim consistency.

Molecular Pathology and NGS Panel Billing

Molecular pathology remains one of the fastest-growing areas in pathology reimbursement.

As precision oncology expands, payers continue increasing review activity around panel selection, medical necessity, and documentation support for advanced molecular testing.

Common Molecular Pathology CPT Codes

81235 → EGFR Gene Analysis

Used for EGFR gene mutation analysis commonly performed in oncology diagnostics to identify actionable mutations guiding targeted cancer therapies. Reports should document tumor type, molecular testing indication, methodology used, and the clinical relevance of detected genomic abnormalities influencing treatment decisions.

81210 → BRAF Gene Analysis

CPT code 81210 covers BRAF mutation analysis performed in oncology testing for melanoma, colorectal cancer, and related malignancies. Proper documentation should identify the gene target evaluated, testing rationale, specimen source, methodology utilized, and the significance of findings for precision oncology treatment planning.

81275 → KRAS Gene Variant Analysis

Reported for KRAS mutation analysis used during molecular oncology evaluation, particularly in colorectal and lung cancer diagnostics. Accurate billing requires documentation of tumor diagnosis, molecular testing indication, laboratory methodology, and interpretation findings supporting targeted therapy or treatment resistance assessment.

NGS Oncology Panel Codes

81445 → Solid Tumor NGS Panel, 5–50 Genes

CPT code 81445 applies to next-generation sequencing panel testing involving five to fifty genes associated with solid organ tumors. Because these claims often face elevated payer scrutiny, laboratories should document panel composition, oncology diagnosis, sequencing methodology, and how genomic findings influence treatment planning decisions.

81450 → Hematolymphoid NGS Panel, 5–50 Genes

Assigned to next-generation sequencing panel testing involving hematolymphoid malignancies with analysis of five to fifty genes. Documentation should support the malignancy evaluated, genes analyzed, sequencing methodology, and the clinical significance of molecular findings guiding hematologic diagnostic and therapeutic workflows.

81455 → Expanded Hematolymphoid NGS Panel, 51+ Genes

Used for expanded next-generation sequencing panel testing involving fifty-one or more genes for hematolymphoid malignancies. These high-complexity molecular studies require strong medical necessity documentation, panel selection rationale, sequencing details, and evidence supporting the clinical utility of the extensive genomic analysis.

Operational Insight

Laboratories should build standardized reflex testing and molecular billing pathways inside the LIS to improve documentation consistency.

Revenue Impact

Molecular pathology services represent significant reimbursement opportunities, but inaccurate panel selection or insufficient medical necessity support can lead to large claim denials and audit exposure.

Outside Pathology Consultation CPT Codes

Outside pathology consultations involve second-opinion pathology review of slides, tissue blocks, or medical records prepared by another laboratory.

Common Consultation CPT Codes

88321 → Outside Slide Consultation and Review

CPT code 88321 is reported when a pathologist performs consultation and interpretation of slides prepared by another laboratory. The service includes diagnostic review and formal report generation. Documentation should identify the originating laboratory, slides reviewed, consultation purpose, and interpretation findings supporting the consultation service.

88323 → Consultation With Slide Preparation From Tissue Blocks

Assigned to pathology consultations requiring preparation of slides from referred tissue blocks before interpretation. The service includes slide preparation, microscopic evaluation, and diagnostic reporting. Documentation should support specimen handling procedures, pathology review performed, and the clinical reason for the consultation request.

88325 → Comprehensive Pathology Consultation

Used for comprehensive pathology consultations involving review of medical records, externally prepared materials, additional studies, and diagnostic interpretation. These services are commonly associated with complex oncology or specialty pathology cases requiring advanced diagnostic expertise and detailed consultation reporting.

Revenue Impact

Outside pathology consultations support specialized diagnostic expertise while creating additional reimbursement opportunities for pathology groups performing advanced review services.

Pathology Modifiers

Modifier accuracy remains one of the largest compliance and reimbursement risks in pathology billing.

Important Pathology Modifiers

Modifier 26 → Professional Component Billing

Modifier -26 is appended when billing only the professional component of a pathology or laboratory service. It represents the physician’s interpretation, diagnostic analysis, and report generation without the technical portion. Pathologists commonly use this modifier when interpretation services are billed separately from laboratory operations.

Modifier TC → Technical Component Billing

Used to identify the technical component of a pathology or laboratory procedure, modifier -TC includes laboratory equipment, specimen preparation, instrumentation, supplies, and technical staff services. This modifier is typically reported when the testing facility bills independently from the physician or pathologist providing diagnostic interpretation.

Modifier 90 → Reference Laboratory Services

Modifier -90 applies when laboratory testing is performed by an outside or reference laboratory rather than the billing provider’s facility. Proper reporting requires documentation identifying the performing laboratory, outsourced testing relationship, and compliance with payer-specific rules governing referred laboratory and pathology testing services.

Modifier 91 → Repeat Laboratory Testing

Modifier -91 supports billing for repeat clinical diagnostic laboratory testing performed on the same date when medically necessary to obtain additional patient results. It should not be used for quality control repeats, confirmatory testing, or duplicate error corrections because payers closely monitor repeat testing utilization patterns.

Modifier 59 → Distinct Procedural Service

Modifier -59 identifies a procedure or laboratory service that is separate and distinct from other services performed on the same date. In pathology billing, it may indicate different specimens, separate anatomical sites, or independent diagnostic circumstances that justify bypassing standard payer bundling or NCCI edit restrictions.

Modifier 92 → Alternative Laboratory Platform Testing

Applied to laboratory testing performed using alternative testing platforms, modifier -92 commonly supports cartridge-based systems, rapid diagnostic kits, or point-of-care technologies rather than conventional laboratory analyzers. Documentation should identify the testing platform used and establish medical necessity for the alternative laboratory testing methodology.

Revenue Impact

Accurate modifier workflows help pathology organizations prevent reimbursement takebacks, split-payment issues, and compliance-related denials.

2026 Pathology CPT Coding Updates Providers Should Monitor

The 2026 CPT updates introduced several new pathology and laboratory codes focused on molecular diagnostics, infectious disease testing, antimicrobial resistance detection, and precision oncology. 

These additions reflect the continued shift toward genomics-driven diagnostics, advanced PCR testing, and algorithm-based risk analysis in laboratory medicine.

For pathology groups and billing teams, the operational impact goes beyond code selection. 

New molecular and Proprietary Laboratory Analysis (PLA) codes require updated documentation workflows, payer policy validation, charge master revisions, and medical necessity support before claims are submitted.

New Molecular and Infectious Disease CPT Codes

CPT Code	2026 Update	Billing Impact
81354	Optical genome mapping for constitutional chromosomal abnormalities	Supports advanced cytogenomic testing reimbursement
81524	CNS tumor DNA methylation analysis	Expands molecular oncology billing opportunities
87182–87183	Carbapenem resistance and enzyme detection	Improves infectious disease specificity
87494	Chlamydia and gonorrhea multiplex probe testing	Enhances STI diagnostic reporting
87627	Joint-space pathogen multiplex testing	Supports expanded infectious disease panels
87812	SARS-CoV-2 and Influenza A/B antigen detection	Reflects ongoing respiratory testing demand

Emerging PLA and Algorithm-Based Laboratory Codes

Several new PLA (Category III/U-codes) focus on:

• AI-assisted oncology risk scoring
• endocrine disease prediction
• advanced antimicrobial susceptibility testing
• reproductive microbiome analysis
• methylation-based cancer diagnostics

Examples include:

• 0603U → Diabetes risk scoring algorithm
• 0609U → Prostate cancer risk analysis
• 0611U – 0612U → Liver cancer methylation profiling
• 0613U → Urothelial carcinoma biomarker analysis

Why These Updates Matter

The 2026 pathology CPT changes reinforce the industry’s transition toward personalized medicine, predictive analytics, and high-complexity molecular testing. Labs that fail to update coding libraries, payer policies, and documentation workflows may experience denials, underbilling, or delayed reimbursement for newer diagnostic services.

Conduct quarterly CPT and payer-policy audits to ensure molecular pathology workflows, LIS systems, and billing teams remain aligned with current 2026 coding requirements.

FAQs 

1. What is the difference between surgical pathology CPT codes 88305 and 88307?

88305 typically applies to moderate-complexity biopsy specimens, while 88307 supports higher-complexity surgical pathology examinations involving larger or more complex resections.

2. Why are pathology modifiers -26 and -TC important?

These modifiers distinguish professional interpretation services from technical laboratory services, helping payers identify which entity performed each component of the pathology work.

3. How do molecular pathology claims get denied?

Common causes include insufficient medical necessity documentation, incorrect panel selection, missing prior authorization, and unsupported oncology diagnoses.

4. What documentation is required for frozen section billing?

Pathology reports should include specimen source, surgeon request, block counts, cytologic preparations, and intraoperative consultation details.

5. Can pathology laboratories bill separately for rapid onsite evaluation during FNA procedures?

Yes. CPT code 88172 may be billed when rapid onsite adequacy evaluation is performed and documented appropriately according to payer guidelines.

6. Why do IHC claims face higher audit scrutiny?

IHC claims often involve higher reimbursement levels, multiple antibody stains, and oncology-related diagnostics, leading payers to review unit reporting and medical necessity carefully.

7. What is the role of CPT code 81445 in molecular pathology billing?

81445 supports next-generation sequencing solid tumor panel testing involving 5–50 genes and is commonly used in oncology diagnostics.

8. How can pathology organizations improve reimbursement accuracy?

Regular coding audits, standardized documentation templates, payer-specific workflow reviews, and denial analysis help improve clean claim performance and reduce compliance risk.